MCID: SCH060
MIFTS: 27

Schistosoma Mansoni Infection, Susceptibility/

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 57
Schistosoma Mansoni Infection, Susceptibility/resistance to 57 13
Schistosomiasis 59 73
Schistosoma Mansoni, Intensity of Infection by; Sm1 57
Schistosoma Mansoni, Intensity of Infection by 57
Bilharziasis 59
Sm1 57

Characteristics:

Orphanet epidemiological data:

59
schistosomiasis
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

OMIM 57 181460
Orphanet 59 ORPHA1247
UMLS via Orphanet 74 C0036323
ICD10 via Orphanet 34 B65.0 B65.1 B65.2 more
MESH via Orphanet 45 D012552
MedGen 42 C1866993
SNOMED-CT via HPO 69 263681008
UMLS 73 C0036323

Summaries for Schistosoma Mansoni Infection, Susceptibility/

MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to schistosomiasis and intestinal schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Lidocaine and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include colon, and related phenotype is abnormality of the immune system.

Description from OMIM: 181460

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 12.7
2 intestinal schistosomiasis 12.5
3 urinary schistosomiasis 12.4
4 cercarial dermatitis 11.9
5 neuroschistosomiasis 11.0
6 hepatic fibrosis, severe due to schistosoma mansoni infection 10.9
7 hepatitis 10.4
8 aging 10.3
9 malaria 10.2
10 bladder cancer 10.2
11 fascioliasis 10.2
12 filariasis 10.1
13 hepatitis c 10.1
14 portal hypertension 10.0
15 cerebritis 10.0
16 hepatitis b 10.0
17 pulmonary hypertension 10.0
18 onchocerciasis 10.0
19 ancylostomiasis 10.0
20 strongyloidiasis 10.0
21 splenomegaly 10.0
22 filarial elephantiasis 10.0
23 ankylostomiasis 9.9
24 small cell cancer of the lung 9.9
25 lung cancer 9.9
26 neuroblastoma 9.9
27 cervicitis 9.9
28 myelitis 9.9
29 transverse myelitis 9.9
30 hepatocellular carcinoma 9.8
31 pulmonary hypertension, primary, 1 9.8
32 endomyocardial fibrosis 9.8
33 squamous cell carcinoma 9.8
34 endotheliitis 9.8
35 hepatitis c virus 9.8
36 liver cirrhosis 9.8
37 thrombosis 9.8
38 trypanosomiasis 9.8
39 paragonimiasis 9.8
40 trachoma 9.8
41 portal vein thrombosis 9.8
42 bacteriuria 9.8
43 dracunculiasis 9.8
44 prostatitis 9.8
45 toxocariasis 9.8
46 toxoplasmosis 9.8
47 asthma 9.7
48 ectopic pregnancy 9.7
49 salmonellosis 9.7
50 cysticercosis 9.7

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:



Diseases related to Schistosoma Mansoni Infection, Susceptibility/

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

Symptoms via clinical synopsis from OMIM:

57
Immunology:
schistosoma mansoni infection susceptibility/resistance


Clinical features from OMIM:

181460

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 32 HP:0002715

Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 71273 175805
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
9
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
10 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
11 Anesthetics, Local Phase 4,Phase 3,Phase 2,Not Applicable
12 Anti-Arrhythmia Agents Phase 4
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
14 Diuretics, Potassium Sparing Phase 4
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Sodium Channel Blockers Phase 4
17 Analgesics Phase 4,Phase 2,Not Applicable
18 Analgesics, Non-Narcotic Phase 4
19 Anti-Anxiety Agents Phase 4,Phase 3
20 Anticonvulsants Phase 4,Phase 3
21 Antiemetics Phase 4,Phase 3
22 Anti-Inflammatory Agents Phase 4
23 Antineoplastic Agents, Hormonal Phase 4
24 Antipyretics Phase 4
25 Autonomic Agents Phase 4,Phase 3,Phase 2
26 BB 1101 Phase 4
27 calcium channel blockers Phase 4
28 Calcium, Dietary Phase 4
29 Dexamethasone acetate Phase 4 1177-87-3
30 Gastrointestinal Agents Phase 4,Phase 3
31 glucocorticoids Phase 4
32 HIV Protease Inhibitors Phase 4
33 Hormone Antagonists Phase 4
34 Hormones Phase 4
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
36
protease inhibitors Phase 4
37 Psychotropic Drugs Phase 4,Phase 3
38 Tranquilizing Agents Phase 4,Phase 3
39 Analgesics, Opioid Phase 4
40 Narcotics Phase 4
41 Adjuvants, Anesthesia Phase 4
42 Anesthetics, General Phase 4
43 Anesthetics, Intravenous Phase 4
44 Narcotic Antagonists Phase 4
45 Cola Nutraceutical Phase 4
46
Diphenhydramine Approved, Investigational Phase 3,Phase 2 147-24-0, 58-73-1 3100
47
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
48
Lorazepam Approved Phase 3,Phase 2 846-49-1 3958
49
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
50
Phenylephrine Approved Phase 3 59-42-7 6041

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2 Completed NCT02172729 Phase 4 Adductor canal block with 20 ml lidocaine, single bolus
2 Effect of Paracetamol,Pregabalin and Dexamethasone on Pain and Opioid Requirements in Postoperative Patients Completed NCT00209495 Phase 4 Pregabalin; Dexamethasone
3 Sensory Distribution of Lateral Femoral Cutaneous Nerve Block Completed NCT02957903 Phase 4 Ropivacaine;Isotonic Saline
4 Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty Completed NCT01549704 Phase 4 Ropivacaine;Saline
5 Method Study: Bilateral TAP Block With 24 Hours Infusion Completed NCT01577940 Phase 4
6 The Efficacy of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction Completed NCT01212666 Phase 4
7 The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty Completed NCT01191593 Phase 4
8 Effect of Transversus Abdominis Plane (TAP) Block After Laparoscopic Colon Surgery Completed NCT01418144 Phase 4
9 The Efficacy of Transversus Abdominis Plane Block After Groin Hernia Repair Completed NCT01052285 Phase 4
10 The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy Completed NCT01046071 Phase 4
11 The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty Completed NCT01104883 Phase 4
12 DEXRAR: DEXamethasone in Revision ARthroplasty Recruiting NCT02884180 Phase 4 Dexamethasone;Saline isotonic
13 The Dexamethasone for Pain Treatment After Total Knee Arthroplasty Trial Not yet recruiting NCT03506789 Phase 4 Dexamethasone;Placebos
14 Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain Suspended NCT00916890 Phase 4 Morphine;Oxycodone;Fentanyl;Buprenorphine
15 Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy Terminated NCT01504386 Phase 4
16 An Investigational Study to Assess the Effectiveness and Safety of SM-1 Versus 2 Comparators and Placebo in Participants With a History of Transient Insomnia. Completed NCT03331042 Phase 3 SM-1;D+Z;D+L;Placebo
17 An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia Not yet recruiting NCT03338764 Phase 3 SM-1;Placebo
18 Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia Completed NCT02671760 Phase 2 SM-1;Comparator;Placebo
19 Does Perineural Clonidine Prolong Duration of a Nerve Block? Completed NCT02444559 Phase 2 Ropivacaine 20ml 5mg/ml+ Clonidine 150ug;Ropivacaine 20ml 5mg/ml+ Placebo
20 Impact of Nutrition Labels on Consumer Purchasing Intentions Completed NCT02385838 Not Applicable
21 Pain Map DK: a Prospective Cohort Study of Pain Treatment in 500 Hip Arthroplasty Patients at Different Danish Hospitals Completed NCT02340052 Pain treatment
22 Characterization of Secondary Hyperalgesia in Healthy Volunteers Completed NCT02166164 Not Applicable
23 Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength, Pain and Mobilization After Total Knee Replacement Completed NCT01470391 Not Applicable
24 The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Following Radical Prostatectomy Completed NCT01317368 Not Applicable Naropine;Naropine
25 The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions Completed NCT01431703
26 Post-endodontic Pain After Single-visit Root Canal Treatment Completed NCT03424655 Not Applicable
27 Piecemeal Versus En Bloc Resection of Large Rectal Adenomas Recruiting NCT02238938 Not Applicable
28 Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery? Not yet recruiting NCT02885142 Not Applicable

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

41
Colon

Publications for Schistosoma Mansoni Infection, Susceptibility/

Variations for Schistosoma Mansoni Infection, Susceptibility/

Expression for Schistosoma Mansoni Infection, Susceptibility/

Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.

Pathways for Schistosoma Mansoni Infection, Susceptibility/

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

Sources for Schistosoma Mansoni Infection, Susceptibility/

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....